emo Bristol-Myers Squibb targeting fibrosis research

More
5 years 8 months ago #22788

Bristol-Myers Squibb appear to be putting some focus on the anti-fibrosis field including investing in licencing rights for development of a promising new drug/delivery system (ND-L02-s0201) that targets HCV and Nash fibrosis.

hepatitiscnewdrugs.blogspot.com.au/2016/...signs-exclusive.html

in.reuters.com/article/us-bristol-myers-...%2F+IN+%2F+Health%29

liverlearning.aasld.org/aasld/2015/theli.../110677/[[$item.link


G3a since '78 - Dx '12 - F4 (2xHCC)
24wk Tx - PEG/Riba/Dac 2013 relapsed
24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 - 22/06/17 UND
SRV12 - 27/07/17 UND
SVR24 - 26/10/17 UND
:cheer: :cheer: :cheer:
Last Edit: 5 years 8 months ago by Gaj.
The following user(s) said Thank You: DrJames, coral, rohcvfighter, fitz

Please Log in or Create an account to join the conversation.

Time to create page: 0.034 seconds

Copyright © 2015-2020 FixHepC

Back to Top